FPRX
Five Prime Therapeutics, Inc.
Set alert
— — —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.77B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -18.45
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 6, 2021
- 50-d avg
- 37.83
- 200-d avg
- 20.74
- 1y target
- 37.00
Key statistics
- Market cap
- 1.77B
- Trailing P/E
- 0.00
- Forward P/E
- -18.45
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 37.83
- 200-day average
- 20.74
Analyst view
Consensus: hold
Hold
Price target (mean) 37.00
- Target (low)
- 33.00
- Target (mean)
- 37.00
- Target (high)
- 38.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy5
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 6, 2021
Expected May 6, 2021. Consensus EPS estimate 0.00.
Financials — quick view
FPRX Revenue — quarterly -708.00K
FPRX Net income — quarterly -20.85M
FPRX EPS — quarterly -0.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2021 | Mar 1, 2021 | -0.54 | — | — | — |
| Nov 3, 2020 | Sep 1, 2020 | -0.61 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | -0.70 | — | — | — |
| May 7, 2020 | Mar 1, 2020 | -0.68 | — | — | — |
| Feb 27, 2020 | Dec 1, 2019 | -0.97 | — | — | — |
| Nov 6, 2019 | Sep 1, 2019 | -0.95 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 9, 2021 | Guggenheim | down | Buy | Neutral |
| Mar 5, 2021 | Jefferies | down | Buy | Hold |
| Nov 11, 2020 | SVB Leerink | reit | — | Outperform |
| Nov 11, 2020 | JP Morgan | up | Underweight | Neutral |
| Nov 11, 2020 | Wells Fargo | up | Equal-Weight | Overweight |
| Nov 4, 2020 | SVB Leerink | main | — | Outperform |
News
- Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
- Prime Time's Revival a Lesson for Biotech Investors
- Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors
- Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
- Why Five Prime Therapeutics (FPRX) Might Surprise This Earnings Season
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Five Prime Therapeutics, Inc. - FPRX
- Five Prime Therapeutics (FPRX) Stock Jumps 78.7%: Will It Continue to Soar?
- 82 Biggest Movers From Yesterday
- FPRX Stock Price Increases 78.74% On Amgen Acquisition News
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Five Prime Therapeutics, Inc.
Your note
Sign in to keep a note on FPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERGER FRANKLIN M | Director | Sale | Dec 2, 2019 | 5,000 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 10, 2020 | 0 |
| CIVIK THOMAS | Chief Executive Officer | Stock Award(Grant) | Apr 12, 2020 | 75,000 |
| COLLINS HELEN LOUISE M.D. | Officer | Stock Award(Grant) | Apr 15, 2021 | 0 |
| KNICKERBOCKER ARON MARC MBA | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 6, 2019 | 0 |
| RINGO WILLIAM R JR | Director | Stock Gift | Apr 4, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.20% | 4,285,161 | 72.89M | Dec 30, 2020 |
| Blackrock Inc. | 6.35% | 2,959,031 | 50.33M | Dec 30, 2020 |
| RTW Investments LP | 5.40% | 2,515,788 | 42.79M | Dec 30, 2020 |
| Vanguard Group, Inc. (The) | 4.45% | 2,070,727 | 35.22M | Dec 30, 2020 |
| Price (T.Rowe) Associates Inc | 3.65% | 1,697,659 | 28.88M | Dec 30, 2020 |
| Invesco Ltd. | 3.60% | 1,677,382 | 28.53M | Dec 30, 2020 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.80% | 1,302,287 | 49.06M | Mar 30, 2021 |
| Vanguard Total Stock Market Index Fund | 2.42% | 1,128,425 | 19.19M | Dec 30, 2020 |
| iShares Russell 2000 ETF | 1.65% | 768,507 | 28.95M | Mar 30, 2021 |
| Price (T.Rowe) New Horizons Fund | 1.53% | 714,691 | 12.16M | Dec 30, 2020 |
| Vanguard Extended Market Index Fund | 1.35% | 626,410 | 10.66M | Dec 30, 2020 |
| Fidelity Select Portfolios - Biotechnology | 1.29% | 603,035 | 13.41M | Feb 27, 2021 |